Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

Immune Design Corp. (IMDZ)

Add IMDZ Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 10/6/2017 4:17:37 PM - Followers: 0 - Board type: Free - Posts Today: 0

Immune Design Corp. 1616 Eastlake Avenue East Suite 310 Seattle, WA 98102 United States Phone: 206-682-0645 Fax: 206-682-0648 Website: Immune Design Corp., a clinical-stage immunotherapy company, engages in the research and development of in vivo immunotherapy treatments. The company develops various product candidates based on its IMDZVex and GLAAS product discovery platforms. Its oncology clinical-stage product candidates include LV305, G305, and CMB305, which are in Phase-I clinical trials for the treatment of solid tumor types, such as breast cancer, melanoma, non-small cell lung cancer, ovarian cancer, or sarcoma. The companys oncology clinical-stage product candidates also comprise G100 that is in Phase-I clinical trials for the treatment of patients with merkel cell carcinoma and sarcoma; and in pre-clinical stage for the treatment of non-Hodgkin lymphoma. It also develops therapies for non-oncology diseases, including infectious diseases, allergy, and autoimmune diseases. The company has license agreements with the California Institute of Technology, University of North Carolina at Chapel Hill, Infectious Disease Research Institute, MedImmune LLC, and Sanofi; collaboration agreements with Sanofi Pasteur, Merck & Co., Inc., and Genentech. Immune Design Corp. was founded in 2008 and is headquartered in Seattle, Washington with additional facilities in South San Francisco, California.
Interactive Brokers Advertisement
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
IMDZ News: Current Report Filing (8-k) 10/16/2017 04:34:22 PM
IMDZ News: Immune Design Announces Positive FDA Feedback on Phase 3 Clinical Trial Design for CMB305 in Synovial Sarcoma Patients 10/16/2017 04:15:00 PM
IMDZ News: Statement of Ownership (sc 13g) 10/06/2017 04:16:13 PM
IMDZ News: Immune Design Announces Four Upcoming Presentations at the SITC 32nd Annual Meeting 09/25/2017 08:00:00 AM
IMDZ News: Amended Statement of Changes in Beneficial Ownership (4/a) 09/22/2017 02:48:21 PM
News News Alert: Current Report Filing (8-k) 10/16/2017 04:34:22 PM
#14   BROOKSIDE CAPITAL MANAGEMENT LLC has filed a new wiltonio 10/06/17 04:17:37 PM
#13   Immune Design (NASDAQ:IMDZ) initiated with Outperform rating and Avispa 08/24/17 08:16:01 AM
#12   Charts show a move to $22 biotechnician 06/27/17 08:16:57 AM
#11   IMDZ bearish 8.30 stocktrademan 11/13/16 04:31:05 PM
#10   The webcast for the second quarter financial results jondoeuk 08/05/16 06:49:27 AM
#9   (A Phase I should be happening some time jondoeuk 07/10/16 04:46:37 AM
#8   New Corporate Overview jondoeuk 07/10/16 04:45:29 AM
#7   Immune Design Releases New PFS, OS and TME jondoeuk 07/10/16 04:43:39 AM
#6   The two abstracts from this year's ASCO meeting jondoeuk 07/10/16 04:42:28 AM
#5   $11.38 chart looks decent for a swing. RealGenius 03/28/16 10:08:25 PM
#4   Thank you. I will email you a few tickers. That's tpizzazz24 11/28/15 10:27:27 AM
#3   Hi Tpizzazz24, stocktrademan 11/27/15 03:04:27 PM
#2   Thanks for the DD. You do a hell of tpizzazz24 11/27/15 12:17:22 PM
#1   $IMDZ recent news/filings stocktrademan 11/25/15 02:07:04 PM